Clinical Trial Update: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pasireotide long-acting release to octreotide long-acting release in active acromegaly completed with results posted in 2015, assessing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Octreotide LAR (octreotide long-acting release)
• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2015-01-30